Patents by Inventor Kapil Bahl
Kapil Bahl has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11911453Abstract: The disclosure relates to respiratory syncytial virus (RSV) ribonucleic acid (RNA) vaccines as well as methods of using the vaccines and compositions comprising the vaccines. The vaccine can be formulated in a lipid nanoparticle.Type: GrantFiled: January 28, 2019Date of Patent: February 27, 2024Assignee: ModernaTX, Inc.Inventors: Giuseppe Ciaramella, Kapil Bahl, Amy Espeseth, Andrew J. Bett, Pedro Cejas, Lan Zhang, Christine Shaw
-
Publication number: 20230390379Abstract: The disclosure relates to respiratory syncytial virus (RSV) ribonucleic acid (RNA) vaccines, as well as methods of using the vaccines and compositions comprising the vaccines.Type: ApplicationFiled: May 10, 2023Publication date: December 7, 2023Applicant: ModernaTX, Inc.Inventors: Giuseppe Ciaramella, Kapil Bahl, Amy Espeseth, Dai Wang, Andrew J. Bett
-
Publication number: 20230114180Abstract: The disclosure relates to respiratory syncytial vims (RSV) ribonucleic acid (RNA) vaccines, as well as methods of using the vaccines and compositions comprising the vaccines.Type: ApplicationFiled: August 30, 2022Publication date: April 13, 2023Applicant: ModernaTX, Inc.Inventors: Giuseppe Ciaramella, Kapil Bahl, Amy Espeseth, Dai Wang, Andrew J. Bett
-
Publication number: 20230020362Abstract: Aspects of the disclosure relate to nucleic acid vaccines. The vaccines include one or more RNA polynucleotides having an open reading frame encoding one or more Chikungunya antigen(s), one or more Zika virus antigens, and one or more Dengue antigens. Methods for preparing and using such vaccines are also described.Type: ApplicationFiled: May 5, 2022Publication date: January 19, 2023Applicant: ModernaTX, Inc.Inventors: Giuseppe Ciaramella, Eric Yi-Chun Huang, Kapil Bahl, Tal Zaks, Sunny Himansu, Sayda Mahgoub Elbashir
-
Patent number: 11464848Abstract: The disclosure describes respiratory syncytial virus (RSV) ribonucleic acid (RNA) vaccines, as well as methods of using the vaccines and compositions comprising the vaccines.Type: GrantFiled: March 15, 2018Date of Patent: October 11, 2022Assignee: ModernaTX, Inc.Inventors: Giuseppe Ciaramella, Kapil Bahl, Amy Espeseth, Dai Wang, Andrew J. Bett
-
Patent number: 11364292Abstract: Aspects of the disclosure relate to nucleic acid vaccines. The vaccines include one or more RNA polynucleotides having an open reading frame encoding one or more Chikungunya antigen(s), one or more Zika virus antigens, and one or more Dengue antigens. Methods for preparing and using such vaccines are also described.Type: GrantFiled: June 10, 2020Date of Patent: June 21, 2022Assignee: ModernaTX, Inc.Inventors: Giuseppe Ciaramella, Eric Yi-Chun Huang, Kapil Bahl, Tal Zaks, Sunny Himansu, Sayda Mahgoub Elbashir
-
Patent number: 11007260Abstract: Aspects of the disclosure relate to nucleic acid vaccines. The vaccines include one or more RNA polynucleotides having an open reading frame encoding one or more Chikungunya antigen(s), one or more Zika virus antigens, and one or more Dengue antigens. Methods for preparing and using such vaccines are also described.Type: GrantFiled: July 21, 2016Date of Patent: May 18, 2021Assignee: ModernaTX, Inc.Inventors: Giuseppe Ciaramella, Eric Yi-Chun Huang, Kapil Bahl, Tai Zaks, Sunny Himansu
-
Publication number: 20210046173Abstract: The disclosure relates to respiratory syncytial virus (RSV) ribonucleic acid (RNA) vaccines as well as methods of using the vaccines and compositions comprising the vaccines. The vaccine can be formulated in a lipid nanoparticle.Type: ApplicationFiled: January 28, 2019Publication date: February 18, 2021Applicant: ModernaTX, Inc.Inventors: Giuseppe Ciaramella, Kapil Bahl, Amy Espeseth, Andrew J. Bett, Pedro Cejas, Lan Zhang, Christine Shaw
-
Publication number: 20200368344Abstract: Aspects of the disclosure relate to nucleic acid vaccines. The vaccines include one or more RNA polynucleotides having an open reading frame encoding one or more Chikungunya antigen(s), one or more Zika virus antigens, and one or more Dengue antigens. Methods for preparing and using such vaccines are also described.Type: ApplicationFiled: June 10, 2020Publication date: November 26, 2020Applicant: ModernaTX, Inc.Inventors: Giuseppe Ciaramella, Eric Yi-Chun Huang, Kapil Bahl, Tal Zaks, Sunny Himansu, Sayda Mahgoub Elbashir
-
Publication number: 20200368343Abstract: Aspects of the disclosure relate to nucleic acid vaccines. The vaccines include one or more RNA polynucleotides having an open reading frame encoding one or more Chikungunya antigen(s), one or more Zika virus antigens, and one or more Dengue antigens. Methods for preparing and using such vaccines are also described.Type: ApplicationFiled: June 10, 2020Publication date: November 26, 2020Applicant: ModernaTX, Inc.Inventors: Giuseppe Ciaramella, Eric Yi-Chun Huang, Kapil Bahl, Tal Zaks, Sunny Himansu
-
Patent number: 10702597Abstract: Aspects of the disclosure relate to nucleic acid vaccines. The vaccines include one or more RNA polynucleotides having an open reading frame encoding one or more Chikungunya antigen(s), one or more Zika virus antigens, and one or more Dengue antigens. Methods for preparing and using such vaccines are also described.Type: GrantFiled: June 15, 2018Date of Patent: July 7, 2020Assignee: ModernaTX, Inc.Inventors: Giuseppe Ciaramella, Eric Yi-Chun Huang, Kapil Bahl, Tal Zaks, Sunny Himansu, Sayda Mahgoub Elbashir
-
Publication number: 20200129608Abstract: The disclosure relates to respiratory syncytial virus (RSV) ribonucleic acid (RNA) vaccines, as well as methods of using the vaccines and compositions comprising the vaccines.Type: ApplicationFiled: March 15, 2018Publication date: April 30, 2020Applicant: ModernaTX, Inc.Inventors: Giuseppe Ciaramella, Kapil Bahl, Amy Espeseth, Dai Wang, Andrew J. Bett
-
Patent number: 10449244Abstract: Aspects of the disclosure describe compositions that comprise RNA polynucleotides having an open reading frame encoding one or more Zika virus antigens. Methods for preparing and using the compositions are also described.Type: GrantFiled: June 15, 2018Date of Patent: October 22, 2019Assignee: ModernaTX, Inc.Inventors: Giuseppe Ciaramella, Eric Yi-Chun Huang, Kapil Bahl, Tal Zaks, Sunny Himansu
-
Publication number: 20190060438Abstract: Aspects of the disclosure relate to nucleic acid vaccines. The vaccines include one or more RNA polynucleotides having an open reading frame encoding one or more Chikungunya antigen(s), one or more Zika virus antigens, and one or more Dengue antigens. Methods for preparing and using such vaccines are also described.Type: ApplicationFiled: July 21, 2016Publication date: February 28, 2019Applicant: ModernaTX, Inc.Inventors: Giuseppe Ciaramella, Eric Yi-Chun Huang, Kapil Bahl, Tal Zaks, Sunny Himansu
-
Publication number: 20180344839Abstract: Aspects of the disclosure relate to nucleic acid vaccines. The vaccines include one or more RNA polynucleotides having an open reading frame encoding one or more Chikungunya antigen(s), one or more Zika virus antigens, and one or more Dengue antigens. Methods for preparing and using such vaccines are also described.Type: ApplicationFiled: June 15, 2018Publication date: December 6, 2018Applicant: ModernaTX, Inc.Inventors: Giuseppe Ciaramella, Eric Yi-Chun Huang, Kapil Bahl, Tal Zaks, Sunny Himansu, Sayda Mahgoub Elbashir
-
Publication number: 20180344838Abstract: Aspects of the disclosure relate to nucleic acid vaccines. The vaccines include one or more RNA polynucleotides having an open reading frame encoding one or more Chikungunya antigen(s), one or more Zika virus antigens, and one or more Dengue antigens. Methods for preparing and using such vaccines are also described.Type: ApplicationFiled: June 15, 2018Publication date: December 6, 2018Applicant: ModernaTX, Inc.Inventors: Giuseppe Ciaramella, Eric Yi-Chun Huang, Kapil Bahl, Tal Zaks, Sunny Himansu
-
Publication number: 20180280496Abstract: Aspects of the disclosure relate to nucleic acid vaccines. The vaccines include one or more RNA polynucleotides having an open reading frame encoding one or more Chikungunya antigen(s), one or more Zika virus antigens, and one or more Dengue antigens. Methods for preparing and using such vaccines are also described.Type: ApplicationFiled: June 15, 2018Publication date: October 4, 2018Applicant: ModernaTX, Inc.Inventors: GIUSEPPE CIARAMELLA, ERIC YI-CHUN HUANG, KAPIL BAHL, TAL ZAKS, SUNNY HIMANSU
-
Publication number: 20180271970Abstract: The disclosure relates to respiratory syncytial virus (RSV) ribonucleic acid (RNA) vaccines, as well as methods of using the vaccines and compositions comprising the vaccines.Type: ApplicationFiled: October 21, 2016Publication date: September 27, 2018Applicant: ModernaTX, INC.Inventors: Giuseppe Ciaramella, Kapil Bahl, Amy Espeseth, Dai Wang, Andrew J. Bett
